Samuel Nordberg, PhD
Articles
Optimizing the Management of TRD
Drs Steven Levine, Patricia Ares-Romero, Samuel Nordberg, Martin Rosenzweig, and Carrie Jardine share insight on the future treatment landscape for TRD.
Payer Strategies to Reduce Delay to TRD Therapy
Dr Martin Rosenzweig discusses the importance of data collection to improve patient care in TRD as well as alternative payment models.
Integrated Policymaking and Measuring Patient Outcomes in TRD
Drs Martin Rosenzweig and Samuel Nordberg share perspectives for integrated policymaking in behavioral health, as well as payer and provider collaboration for TRD.
Navigating Payer Policies for Alternative Therapies in TRD
Carrie Jardine leads a discussion on varying prior authorization policies for alternative therapies for TRD along with implications to patients.
Benefit Design and Overcoming Barriers to Access for Alternative Therapies in TRD
Carrie Jardine and Martin Rosenzweig, MD, share considerations for benefit design in behavioral health.
Risk Evaluation and Mitigation Strategies for Intranasal Esketamine in TRD
Experts in behavioral health discuss overcoming barriers to access for alternative therapies for TRD including the Risk Evaluation and Mitigation Strategy (REMS) requirement for intranasal esketamine.
Alternative Treatment Options for TRD
Dr Patricia Ares-Romero and Dr Martin Rosenzweig discuss treatment strategies for TRD, including alternative therapies and explain current barriers within the healthcare system that inhibit access.
Patient Barriers to Access Treatment for TRD
Dr Samuel Nordberg and Carrie Jardine discuss barriers to access to care for patients with TRD and provide insight on addressing these concerns to achieve optimal care.
Risk Factors for TRD and Payer Considerations
Patricia Ares-Romero, MD, reviews the frequency of TRD diagnosis and common risk factors, and Martin Rosenzweig, MD, explores patient identification and economic burden of disease.
